Drug Search Results
More Filters [+]

Glutaral

Alternative Names: glutaral, ginkgo biloba extract
Latest Update: 2024-08-21
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: P-gp Inhibitor,TNF Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Argentina | Australia | Chile | Colombia | Dominican Republic | Germany | India | Ireland | Korea | Lebanon | Malaysia | Mexico | Morocco | Pakistan | Peru | Russia | Spain | Taiwan | Thailand | Turkey | United Arab Emirates | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Amen Clinics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Glutaral

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Hearing Loss, Sudden|Cognitive Dysfunction|Sleep Apnea, Obstructive|Deafness|Myocardial Ischemia|Coronary Artery Disease|Glaucoma|Type 2 Diabetes|Cognition Disorders|Alzheimer Disease

Phase 3: Memory Disorders|Cognitive Dysfunction|Dementia|Tinnitus

Phase 2: Hearing Loss|Fetal Growth Retardation|Type 2 Diabetes|Insulin Resistance|Raynaud Disease

Phase 1: Coronary Disease|Angina Pectoris

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BEFIT

N/A

Not yet recruiting

Ischemic Stroke

2026-10-01

GRACE

P4

Not yet recruiting

Cognitive Dysfunction

2025-12-31

ChiCTR2200063158

N/A

Not yet recruiting

Unknown

2024-12-31

BTCHENT201901

P4

Recruiting

Sleep Apnea, Obstructive|Deafness|Hearing Loss, Sudden

2024-12-01

Recent News Events